Equities analysts expect Lannett Company, Inc. (NYSE:LCI) to report sales of $176.30 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Lannett’s earnings, with the highest sales estimate coming in at $182.14 million and the lowest estimate coming in at $172.60 million. Lannett reported sales of $165.72 million in the same quarter last year, which would indicate a positive year over year growth rate of 6.4%. The company is expected to report its next earnings results on Tuesday, May 1st.
On average, analysts expect that Lannett will report full year sales of $176.30 million for the current fiscal year, with estimates ranging from $681.80 million to $714.17 million. For the next fiscal year, analysts forecast that the company will post sales of $686.96 million per share, with estimates ranging from $653.68 million to $742.74 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Lannett.
Lannett (NYSE:LCI) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.20. The company had revenue of $184.31 million during the quarter, compared to analyst estimates of $190.92 million. Lannett had a net margin of 7.44% and a return on equity of 18.85%. Lannett’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.92 EPS.
In related news, major shareholder David Farber sold 10,000 shares of Lannett stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $25.01, for a total value of $250,100.00. Following the completion of the sale, the insider now owns 4,171,269 shares of the company’s stock, valued at approximately $104,323,437.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 14.72% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. LSV Asset Management grew its position in Lannett by 2.2% in the 4th quarter. LSV Asset Management now owns 1,835,535 shares of the company’s stock valued at $42,584,000 after purchasing an additional 40,000 shares during the period. Thompson Siegel & Walmsley LLC grew its position in Lannett by 20.5% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,010,232 shares of the company’s stock valued at $18,639,000 after purchasing an additional 171,751 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in Lannett in the 4th quarter valued at $21,367,000. Russell Investments Group Ltd. grew its position in Lannett by 27.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 669,298 shares of the company’s stock valued at $12,349,000 after purchasing an additional 142,278 shares during the period. Finally, Deutsche Bank AG grew its position in Lannett by 3.7% in the 4th quarter. Deutsche Bank AG now owns 415,219 shares of the company’s stock valued at $9,631,000 after purchasing an additional 14,992 shares during the period. 98.40% of the stock is owned by institutional investors and hedge funds.
Lannett stock traded down $0.85 during trading hours on Thursday, hitting $15.65. 1,299,485 shares of the stock traded hands, compared to its average volume of 690,393. The company has a market cap of $592.26, a price-to-earnings ratio of 12.32, a P/E/G ratio of 1.00 and a beta of 2.63. The company has a quick ratio of 1.77, a current ratio of 2.32 and a debt-to-equity ratio of 1.38. Lannett has a 12 month low of $14.90 and a 12 month high of $30.35.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.